Immuno-Oncology | Specialty

REGINA Data Support Further Evaluation of Neoadjuvant Regorafenib, Nivolumab, and SCRT in Rectal Cancer

July 8th 2024

Data from the phase 2 REGINA trial support further investigation of neoadjuvant regorafenib, nivolumab, and SCRT in locally advanced rectal cancer.

Liao Emphasizes the Importance of Multidisciplinary Collaboration in HCC

July 5th 2024

Chih-Yi Liao, MD, discusses treatment considerations for patients with hepatocellular carcinoma and emphasizes the need for a multidisciplinary approach.

Liao Highlights Treatment Selection Considerations and Key Data in Biliary Tract Cancer

July 3rd 2024

Chih-Yi Liao, MD, discusses the treatment landscape of advanced biliary tract cancer and outlines therapy selection factors.

Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer

July 3rd 2024

Dostarlimab plus chemotherapy demonstrated a meaningful overall survival improvement in primary endometrial cancer, regardless of mismatch repair status.

Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer

July 1st 2024

The EMA recommends durvalumab plus chemotherapy, followed by olaparib and durvalumab for pMMR endometrial cancer, and single-agent durvalumab for dMMR disease.

Durvalumab Plus Chemo Maintains OS Benefit in Advanced Biliary Tract Cancer

July 1st 2024

Durvalumab plus chemotherapy sustained an overall survival benefit vs chemotherapy alone in locally advanced or metastatic biliary tract cancer.

Pembrolizumab Plus Bevacizumab/CAPOX Yields Responses in pMMR/MSS mCRC With High TILs

July 1st 2024

Pembrolizumab plus bevacizumab and CAPOX produced responses in pMMR/MSS metastatic colorectal cancer with high immune infiltrate.

Revisit Every OncLive On Air Episode From June 2024

July 1st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in June 2024.

MPO Could Represent Predictive OS Biomarker for CM24 Plus Nivolumab/Chemo in Second-Line PDAC

June 27th 2024

MPO may be a predictive biomarker for survival for treatment with CM24, nivolumab, and chemotherapy in second-line pancreatic ductal adenocarcinoma.

Effects of Cancer Drug Shortages Linger as New Survey Results Show Impacts on Clinical Trials

June 26th 2024

Eighty-nine percent of cancer centers are experiencing shortages of at least 1 systemic therapy, impacting clinical trials at 43% of centers.

Sacituzumab Govitecan/Enfortumab Vedotin ± Pembrolizumab Under Investigation in Metastatic Urothelial Carcinoma

June 26th 2024

Bradley McGregor, MD, on the ongoing evaluation of sacituzumab govitecan plus enfortumab vedotin with or without pembrolizumab in urothelial carcinoma.

Perioperative Durvalumab Plus Chemo Meets EFS, OS End Points in MIBC

June 25th 2024

Perioperative durvalumab demonstrated a statistically significant improvement in EFS and OS in muscle-invasive bladder cancer.

Addressing the Logistics of At-Home Cancer Care With Subcutaneous Administration of Immunotherapy

June 25th 2024

Jorge J. Nieva, MD, details the role of telemedicine for patients with non–small cell lung cancer and a first-of-its-kind study examining atezolizumab given subcutaneously at home.

ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma

June 20th 2024

ROCSAN step 1 did not meet its primary end point of 16-week response rate with niraparib or dostarlimab/niraparib in endometrial/ovarian carcinosarcoma.

Multidisciplinary- and Precision-Based Approaches Enhance Treatment in NSCLC

June 18th 2024

Eric Vallieres, MD, FRCSC, discussed recent advancements in surgical oncology regarding the treatment of patients with non–small cell lung cancer (NSCLC)

China’s NMPA Gives Go Ahead to Toripalimab Plus Chemotherapy in First-Line ES-SCLC

June 18th 2024

Toripalimab in combination with etoposide and platinum has been approved by the NMPA in China in first-line extensive-stage small cell lung cancer.

FDA Approves Pembrolizumab Plus Chemotherapy for Advanced/Recurrent Endometrial Carcinoma

June 17th 2024

The FDA has approved pembrolizumab plus carboplatin and paclitaxel, followed by pembrolizumab alone, for primary advanced or recurrent endometrial carcinoma.

FDA Approves Durvalumab Plus Chemotherapy for dMMR Primary Advanced or Recurrent Endometrial Cancer

June 14th 2024

The FDA had approved durvalumab plus, followed by single-agent durvalumab, for dMMR primary advanced or recurrent endometrial cancer.

A Surgeon’s Perspective: How to Optimize Outcomes With Neoadjuvant Chemo/IO in Lung Cancer

June 13th 2024

Eric Vallieres, MD, FRCSC, discusses the evolving role of surgery in lung cancer treatment following the implementation of new neoadjuvant and adjuvant treatments.

Frontline Petosemtamab Doublet Elicits Responses in Recurrent/Metastatic HNSCC

June 4th 2024

Petosemtamab paired with pembrolizumab had early clinical efficacy when used as first-line treatment in select head and neck squamous cell carcinoma